NAMI
TBPH icon

Nomura Asset Management International’s Theravance Biopharma TBPH Stock Holding History

Nomura Asset Management International’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.55M Hold
208,783
– – 0.01% 926
2026
Q1 		$3.39M Hold
208,783
– – 0.01% 857
2025
Q4 		$3.91M Buy
+208,783
New +$3.46M 0.01% 837

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Nomura Asset Management International's TBPH Position: Q2 2026 in Review

Nomura Asset Management International held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 208,783 shares worth $3.55M. The position accounts for 0.01% of the portfolio, ranked #926.

Nomura Asset Management International first reported a position in TBPH in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.91M in Q4 2025. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Nomura Asset Management International held 208,783 shares of Theravance Biopharma worth $3.55M as of Q2 2026.
  • Nomura Asset Management International left its Theravance Biopharma share count unchanged in Q2 2026.
  • Theravance Biopharma made up 0.01% of Nomura Asset Management International's portfolio in Q2 2026, its #926 holding.
  • Nomura Asset Management International first reported a position in Theravance Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Nomura Asset Management International's Theravance Biopharma position peaked at $3.91M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.